Repligen Corp. Stock
Price
Target price
€108.60
€108.60
1.110%
1.2
1.110%
€172.32
04.07.25 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
There is an upward development for Repligen Corp. compared to yesterday, with an increase of €1.20 (1.110%).
With 15 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 172 € there is a hugely positive potential of 58.38% for Repligen Corp. compared to the current price of 108.6 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 1.110% | 2.841% | -3.552% | -2.949% | -22.401% | -31.801% | -3.894% |
| Opko Health Inc. | -4.000% | 0.037% | -7.137% | -1.401% | -22.995% | -58.071% | -66.808% |
| Amicus Therapeutics Inc. | 3.000% | 6.846% | 0.000% | -42.458% | -43.716% | -51.036% | -62.681% |
| Indivior plc | 2.310% | 8.333% | 7.438% | -6.475% | 9.244% | -28.137% | 138.751% |
Comments
Repligen Corporation (NASDAQ: RGEN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $150.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
